1592 related articles for article (PubMed ID: 7641363)
1. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.
Azizi M; Chatellier G; Guyene TT; Murieta-Geoffroy D; Ménard J
Circulation; 1995 Aug; 92(4):825-34. PubMed ID: 7641363
[TBL] [Abstract][Full Text] [Related]
2. Additive effects of losartan and enalapril on blood pressure and plasma active renin.
Azizi M; Guyene TT; Chatellier G; Wargon M; Ménard J
Hypertension; 1997 Feb; 29(2):634-40. PubMed ID: 9040450
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological demonstration of the additive effects of angiotensin-converting enzyme inhibition and angiotensin II antagonism in sodium depleted healthy subjects.
Azizi M; Guyene TT; Chatellier G; Ménard J
Clin Exp Hypertens; 1997; 19(5-6):937-51. PubMed ID: 9247766
[TBL] [Abstract][Full Text] [Related]
4. Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man.
Schmitt F; Natov S; Martinez F; Lacour B; Hannedouche TP
Clin Sci (Lond); 1996 Mar; 90(3):205-13. PubMed ID: 8777826
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.
Nussberger J; Wuerzner G; Jensen C; Brunner HR
Hypertension; 2002 Jan; 39(1):E1-8. PubMed ID: 11799102
[TBL] [Abstract][Full Text] [Related]
6. Comparative effect of angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor antagonism on plasma fibrinolytic balance in humans.
Brown NJ; Agirbasli M; Vaughan DE
Hypertension; 1999 Aug; 34(2):285-90. PubMed ID: 10454455
[TBL] [Abstract][Full Text] [Related]
7. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.
Gainer JV; Morrow JD; Loveland A; King DJ; Brown NJ
N Engl J Med; 1998 Oct; 339(18):1285-92. PubMed ID: 9791144
[TBL] [Abstract][Full Text] [Related]
8. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers.
Goldberg MR; Tanaka W; Barchowsky A; Bradstreet TE; McCrea J; Lo MW; McWilliams EJ; Bjornsson TD
Hypertension; 1993 May; 21(5):704-13. PubMed ID: 8491505
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin-converting enzyme gene polymorphism has no influence on the circulating renin-angiotensin-aldosterone system or blood pressure in normotensive subjects.
Lachurié ML; Azizi M; Guyene TT; Alhenc-Gelas F; Ménard J
Circulation; 1995 Jun; 91(12):2933-42. PubMed ID: 7796503
[TBL] [Abstract][Full Text] [Related]
10. Add-on angiotensin receptor blockade with maximized ACE inhibition.
Agarwal R
Kidney Int; 2001 Jun; 59(6):2282-9. PubMed ID: 11380832
[TBL] [Abstract][Full Text] [Related]
11. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels.
Komine N; Khang S; Wead LM; Blantz RC; Gabbai FB
Am J Kidney Dis; 2002 Jan; 39(1):159-64. PubMed ID: 11774115
[TBL] [Abstract][Full Text] [Related]
12. Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight, and renin in spontaneously hypertensive rats.
Ménard J; Campbell DJ; Azizi M; Gonzales MF
Circulation; 1997 Nov; 96(9):3072-8. PubMed ID: 9386177
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.
Massien C; Azizi M; Guyene TT; Vesterqvist O; Mangold B; Ménard J
Clin Pharmacol Ther; 1999 Apr; 65(4):448-59. PubMed ID: 10223783
[TBL] [Abstract][Full Text] [Related]
14. Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system.
Stephan D; Grima M; Welsch M; Barthelmebs M; Vasmant D; Imbs J
Fundam Clin Pharmacol; 1996; 10(5):474-83. PubMed ID: 8902551
[TBL] [Abstract][Full Text] [Related]
15. Effects of captopril, an angiotensin-converting enzyme inhibitor, in normotensive sodium-replete volunteers.
Shepherd AN; Campbell BC; Reid JL
J Cardiovasc Pharmacol; 1982; 4(3):381-7. PubMed ID: 6177933
[TBL] [Abstract][Full Text] [Related]
16. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors.
Ferrario CM; Jessup J; Gallagher PE; Averill DB; Brosnihan KB; Ann Tallant E; Smith RD; Chappell MC
Kidney Int; 2005 Nov; 68(5):2189-96. PubMed ID: 16221218
[TBL] [Abstract][Full Text] [Related]
17. Modulation of renal glomerular angiotensin II receptors by ace inhibition and AT1 receptor antagonism.
Haddad G; Amiri F; Garcia R
Regul Pept; 1997 Jan; 68(2):111-7. PubMed ID: 9110382
[TBL] [Abstract][Full Text] [Related]
18. Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension.
van den Meiracker AH; Admiraal PJ; Derkx FH; Kleinbloesem C; Man in 't Veld AJ; van Brummelen P; Mulder P; Schalekamp MA
J Hypertens; 1993 Aug; 11(8):831-8. PubMed ID: 8228207
[TBL] [Abstract][Full Text] [Related]
19. Neurohormonal reactivation in heart failure patients on chronic ACE inhibitor therapy: a longitudinal study.
Lee AF; MacFadyen RJ; Struthers AD
Eur J Heart Fail; 1999 Dec; 1(4):401-6. PubMed ID: 10937954
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.
Azizi M; Bissery A; Peyrard S; Guyene TT; Ozoux ML; Floch A; Ménard J
Clin Pharmacol Ther; 2006 Jan; 79(1):49-61. PubMed ID: 16413241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
